Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeritas gets US nod to use V-Go device to deliver Novo Nordisk's insulin

This article was originally published in Clinica

Executive Summary

The US FDA has granted 510(k) clearance for the use of the V-Go disposable insulin delivery device, developed by Valeritas, with Novo Nordisk's NovoLog, a fast-acting form of insulin. V-Go permits continuous subcutaneous delivery of insulin in preset basal rates, along with on-demand bolus dosing for adult patients. Patients with type 2 diabetes apply a new V-Go to the skin daily for 24 hours. In December, the FDA cleared use of the V-Go with Eli Lilly's Humalog fast-acting insulin. NovoLog and Humalog are the two most widely prescribed fast-acting insulins in the US, Bridgewater, New Jersey-based Valeritas says.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel